Drug Discovery Technologies Market by Product (Instruments, Reagents, Software), Technology (HTS, NGS, PCR, AI-based, Lab-on-chip), Process (Target Identification, Validation, Lead Optimization), Therapeutic Area (Oncology, CVD) - Global Forecast to 2030

The drug discovery technologies market is expected to reach USD 51.51 billion in 2030 from USD 30.58 billion in 2025, at a CAGR of 11.0% during the forecast period. The market is driven by the increasing adoption of advanced screening platforms and the shift toward 3D cell cultures, organoids, and organ-on-a-chip models. These technologies improve disease relevance, enhance predictive accuracy, and support more efficient and reliable drug discovery processes. Furthermore, the shift towards targeted and precision therapies further boosts demand. However, high technology costs, complex workflows, and the need for skilled professionals continue to limit market growth.

The in-silico/AI-based drug discovery segment is expected to grow at the highest CAGR during the forecast period.

The in silico/AI-based drug discovery technology segment is growing at the highest CAGR in the drug discovery technologies market due to its ability to shorten discovery timelines, reduce costs, and improve success rates. These technologies use computational modeling, machine learning, and data analytics to rapidly identify and optimize drug candidates. By analyzing large biological and chemical datasets, AI-based platforms enable accurate target identification, lead screening, and toxicity prediction at early stages. This reduces reliance on trial-and-error laboratory methods and minimizes late-stage failures. Their scalability, speed, and ability to support precision medicine make in silico and AI-based technologies essential tools for pharmaceutical and biotechnology companies, driving strong adoption across the market.

The oncology segment holds the largest share of the market.

The oncology segment accounts for the largest share of the Drug Discovery Technologies Market. This growth is driven by the increasing prevalence of cancer worldwide and the rising focus on developing targeted and personalized therapies. Advanced screening platforms, high-throughput assays, and cell-based models are widely used to identify potential drug candidates, validate targets, and optimize leads. Strong investments in cancer research, expanding clinical pipelines, and growing collaboration between pharmaceutical companies and research institutes further support the adoption of these technologies. Improved drug development efficiency and the demand for more effective cancer treatments continue to drive growth in this segment globally.

The US is expected to grow at the highest CAGR during the forecast period.

The US is experiencing the highest growth in the drug discovery technologies market due to several factors. A strong presence of leading pharmaceutical and biotech companies, advanced research infrastructure, and a large number of ongoing oncology programs are key drivers. Increasing adoption of high-throughput screening, 3D cell models, and organ-on-a-chip platforms in cancer research is fueling demand. Supportive regulations, substantial public and private funding for biomedical research, and a focus on precision medicine further contribute to market expansion. Widespread use of advanced discovery technologies and robust collaborations between industry and research institutes enhance innovation, ensuring high-quality outputs and reinforcing North America’s leading position globally.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side – 70% and Demand Side– 30%
• By Designation: Managers – 45%, CXOs and Directors – 30%, and Executives – 25%
• By Region: North America – 40%, Europe – 25%, Asia Pacific – 25%, Latin America – 5%, the Middle East & Africa – 5%

Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Agilent Technologies, Inc. (US), Illumina, Inc. (US), Revvity (US), F. Hoffmann-La Roche Ltd (Switzerland), Bruker (US), QIAGEN (Germany), Bio-Rad Laboratories, Inc. (US), Tecan Trading AG (Switzerland), Takara Bio Inc. (Japan), Corning Incorporated (US), Hamilton Company (US), PacBio (US), Oxford Nanopore Technologies plc (UK), Promega Corporation (US), Waters Corporation (US), Merck KGAA (Germany), Sartorius AG (Germany), BD (US), Eppendorf SE (Germany), Shimadzu Corporation (Japan), Aurora Biomed Inc. (Canada), Standard BioTools (US), Jeol Ltd. (Japan), Gilson Incorporated (US), BIOMÉRIEUX (France), Greiner AG (Austria), BGI Group (China), Porvair (UK), Polaris Genomics (US), BICO (Sweden), Creative Bioarray (US), Sphere Bio (UK), GenScript (UK), Schrödinger, Inc. (US), LECO Corporation (US), TransGen Biotech Co., Ltd. (China), BMG LABTECH (Germany), NanoTemper Technologies (Germany), MGI Tech Co., Ltd. (China), Araceli Biosciences (US), Sphere Bio (US), BioSolvelT GmbH (Germany), and Evosep (Denmark) are some of the key companies offering drug discovery technologies products.

Research Coverage

This research report categorizes the drug discovery technologies market by product (reagents & consumables, instruments, bioinformatics tools & software), technology (high-throughput screening technologies, next-generation sequencing, polymerase chain reaction, in-silico/AI-based drug discovery technologies, X-ray crystallography, chromatography, mass spectrometry, other technologies), process (target identification, target validation, hit-to-lead identification, lead optimization, candidate validation), therapeutic area (oncology, infectious diseases, cardiovascular diseases, neurological diseases, endocrine & metabolic diseases, autoimmune disorders, other therapeutic areas), end user (pharmaceutical & biotechnology companies, academic & research institutes, contract research organizations (CROs), other end users), and region (North America, Europe, Asia Pacific, Latin America, Middle East, And Africa).

The report’s scope encompasses detailed information about the primary factors, including drivers, restraints, challenges, and opportunities, that influence the growth of the drug discovery technologies market. A comprehensive analysis of key industry players has been performed to provide insights into their business overview, product portfolio, key strategies, new product launches, acquisitions, and recent developments related to the drug discovery technologies market. This report also includes a competitive analysis of emerging startups in the drug discovery technologies industry ecosystem.

Key Benefits of Buying the Report

The report will assist market leaders and new entrants by providing revenue estimates for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market's pulse and offer information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (increasing adoption of advanced screening platforms, shift toward biologics and advanced therapeutic modalities, transition from conventional two-dimensional cultures to three-dimension models, technological innovations in assay miniaturization and automation), restraints (high up-front investment in instruments, automation, and data infrastructure and shortage of skilled personnel), opportunities (growing demand for in-silico based discovery and increasing need for specialized ADME/Toxicology testing), and challenges (assay reproducibility and standardization issues) influencing the market growth
• Product Development/Innovation: Detailed insights into newly launched products and technological assessment of the drug discovery technologies market
• Market Development: Comprehensive information about lucrative markets and analysis of the market across varied regions
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the drug discovery technologies market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players, including Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Agilent Technologies, Inc. (US), Illumina, Inc. (US), Revvity (US), among others, offering products for the drug discovery technologies market. Other companies include Polaris Genomics (US), BICO (Sweden), Creative Bioarray (US), Sphere Bio (UK), GenScript (UK), Schrödinger, Inc. (US), LECO Corporation (US), among others, for the drug discovery technologies market.

Show more